Placebo + Mirogabalin
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Central Neuropathic Pain
Conditions
Central Neuropathic Pain
Trial Timeline
Mar 12, 2019 → Dec 28, 2020
NCT ID
NCT03901352About Placebo + Mirogabalin
Placebo + Mirogabalin is a phase 3 stage product being developed by Daiichi Sankyo for Central Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT03901352. Target conditions include Central Neuropathic Pain.
What happened to similar drugs?
4 of 19 similar drugs in Central Neuropathic Pain were approved
Approved (4) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03901352 | Phase 3 | Completed |
Competing Products
20 competing products in Central Neuropathic Pain